Phaseline

Targets › SNARE

SNARE: drug programs, companies and trials

11 programs from 10 companies in 12 trials: 5 Phase 2, 4 Phase 3, 2 Phase 4, 1 Phase 1; Genitourinary, Other, Psychiatry; next expected readout Dec 2026.

Open in Phaseline: the race on SNARE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boston Medical CenterprabotulinumtoxinA-xvfs
Botulinum toxin serotype A; cleaves SNARE proteins to inhibit acetylcholine release at the
SNAREPhase 4Neck Muscle IssueMar 2027
David M. SimpsonAbobotulinum toxin A (Dysport)
Botulinum toxin type A; cleaves SNARE proteins to inhibit acetylcholine release at neuromu
SNAREPhase 4Tremor, Limb–
Region StockholmBotulinum toxin A (5U/0.1 ml)
Neuromuscular blocking agent; cleaves SNARE proteins to inhibit acetylcholine release
SNAREPhase 3Temporomandibular DisorderDec 2026
University Hospital, Rouenintra-rectal botulinum toxin injections
SNARE complex inhibitor; blocks acetylcholine release at neuromuscular junction
SNAREPhase 3Fecal IncontinenceJun 2027
Assistance Publique - Hôpitaux de ParisBTA (XEOMIN®)
Botulinum toxin A - reversible neuromuscular blockade inducing flaccid paralysis of latera
SNAREPhase 3Incisional HerniaAug 2028
Copenhagen University Hospital, RigshospitaletIncobotulinumtoxin-A
Botulinum toxin A that cleaves SNARE proteins to inhibit acetylcholine release at the neur
SNAREPhase 2Diabetic Neuropathy, PainfulMay 2027
Vensica TherapeuticsNT 201 200U
Botulinum toxin type A
SNAREPhase 2Overactive Bladder (OAB)Sep 2027
Vensica TherapeuticsNT 201 300U
Botulinum toxin type A
SNAREPhase 2Overactive Bladder (OAB)Sep 2027
Abdallah Mohamed Abdallah Mohamed Elgendy25 units Botulinum Toxin-A
Botulinum toxin serotype A; cleaves SNARE complex proteins to block acetylcholine release
SNAREPhase 2Premature Ejaculation–
Eirion TherapeuticsAI-09 Ready Use Injectable Botulinum Toxin
Botulinum toxin type A - cleaves SNARE proteins, blocking acetylcholine release at the neu
SNAREPhase 2Glabellar Lines–
University of MiamiBotulinum neurotoxin
SNARE complex inhibitor; presynaptic acetylcholine release inhibitor
SNAREPhase 1Pelvic Floor DisordersMar 2027

Conditions

Overactive Bladder (OAB) (2) Temporomandibular Disorder (2) Fecal Incontinence (1) Premature Ejaculation (1) Tremor, Limb (1) Diabetic Neuropathy, Painful (1) Pelvic Floor Disorders (1) Incisional Hernia (1) Neck Muscle Issue (1) Glabellar Lines (1)

Modalities

protein or peptide (7), small molecule (2), other (2)

Companies

Vensica Therapeutics (2) University Hospital, Rouen (1) Abdallah Mohamed Abdallah Mohamed Elgendy (1) David M. Simpson (1) Copenhagen University Hospital, Rigshospitalet (1) University of Miami (1) Assistance Publique - Hôpitaux de Paris (1) Boston Medical Center (1) Region Stockholm (1) Eirion Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.